<DOC>
	<DOCNO>NCT02203032</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety guselkumab ( CNTO 1959 ) treatment participant moderate severe plaque-type psoriasis ( scaly skin rash ) inadequate response ustekinumab .</brief_summary>
	<brief_title>A Study Guselkumab Participants With Moderate Severe Plaque-type Psoriasis Inadequate Response Ustekinumab</brief_title>
	<detailed_description>This randomize ( assignment study drug chance ) , double-blind ( participant study staff know identity study drug ) , multicenter study evaluate efficacy safety guselkumab treatment participant moderate severe plaque-type psoriasis inadequate response ustekinumab . The study consist screening period , open-label double-blind treatment period , follow-up period . The treatment period 2 phase : open-label treatment phase participant receive ustekinumab Weeks 0 4 blind treatment phase participant inadequate Investigator 's Global Assessment response ( IGA≥2 ) ustekinumab Week 16 randomize receive either guselkumab ustekinumab Week 44 . Participants IGA response 0 1 ( clear minimal disease ) Week 16 continue receive open-label treatment ustekinumab every 12 week Week 40 . All participant complete follow-up phase Week 52 efficacy Week 60 safety evaluation . The total duration study approximately 64 week ( include 4-week screening period ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis ( without psoriatic arthritis least 6 month first administration study drug Have Psoriasis Area Severity Index ( PASI ) great equal ( &gt; = ) 12 Screening Baseline Have Investigator 's Global Assessment ( IGA ) &gt; =3 Screening Baseline Have involve body surface area ( BSA ) &gt; = 10 percent ( % ) Screening Baseline Be candidate phototherapy systemic treatment psoriasis ( either naïve history previous treatment ) Has history current sign symptom severe , progressive , uncontrolled renal , hepatic , cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance Has unstable cardiovascular disease , define recent clinical deterioration ( example [ eg ] , unstable angina , rapid atrial fibrillation ) last 3 month cardiac hospitalization within last 3 month Currently malignancy history malignancy within 5 year Screening ( exception nonmelanoma skin cancer adequately treat evidence recurrence least 3 month first study drug administration , cervical carcinoma situ treat evidence recurrence least 3 month first study drug administration ) Has previously receive guselkumab ustekinumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque-type psoriasis</keyword>
	<keyword>Guselkumab</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>CNTO 1959</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>